IMMUNOMEDICS, INC.

Basic Information

300 The American Road
Morris Plains, NJ, 07950-

Company Profile

n/a

Additional Details

Field Value
DUNS: 115350605
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    Amount: $213,982.00

    DESCRIPTION (provided by applicant): The overall goal of this SBIR application is to initiate a clinical trial with a bispecific antibody (bsMAb) pretargeting procedure for detecting pancreatic carci ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. CBT Supervisor's Toolkit: Phase II

    Amount: $200,782.00

    DESCRIPTION (provided by applicant): Triple-negative breast cancer (TNBC) is a subset of breast cancers with poor prognosis and high mortality due to the lack of effective therapeutic regimens. This P ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Combined radio- and immunotherapy of aggressive NHL

    Amount: $1,137,221.00

    DESCRIPTION (provided by applicant): The main goal of this Phase I/II SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherapy ...

    SBIR Phase II 2013 Department of Health and Human Services
  4. Bispecific antibody pretargeted immunoPET of prostate cancer

    Amount: $276,833.00

    DESCRIPTION (provided by applicant): This Phase I application is being submitted with the main objective to develop a highly sensitive and specific imaging method for prostate cancer that is based on ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Humanized Anti-Trop2-SN-38 Conjugate For Advanced Pancreatic Cancer

    Amount: $227,025.00

    DESCRIPTION (provided by applicant): The main objective of this Phase I SBIR application is to perform the first-in-man studies with a new antibody-drug conjugate (ADC) composed of a humanized antibo ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Use of milatuzumab in modulating graft vs. host disease

    Amount: $191,143.00

    DESCRIPTION (provided by applicant): Control of GVHD by milatuzumab in hu-SCID mice Dendritic cells (DCs) are the primary initiator of graft-versus-host disease (GVHD), a major and life- threatening c ...

    STTR Phase I 2011 Department of Health and Human Services
  7. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy

    Amount: $2,828,870.00

    DESCRIPTION (provided by applicant): As a continuation of a successful Phase I SBIR, this Phase II application is directed towards the further development of a novel immunocytokine, named 20-2b, for i ...

    SBIR Phase II 2010 Department of Health and Human Services
  8. F-18 Labeled Peptides for Pretargeted PET Imaging of Pancreatic Cancer

    Amount: $1,122,960.00

    DESCRIPTION (provided by applicant): Our primary interest is to develop an imaging method based on bispecific antibody (bsMAb) pretargeting used in combination with F-18 labeled peptides. Such a metho ...

    SBIR Phase II 2009 Department of Health and Human Services
  9. Combined radio- and immunotherapy of aggressive NHL

    Amount: $859,792.00

    DESCRIPTION (provided by applicant): The main goal of this Phase I/II SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherap ...

    SBIR Phase I 2009 Department of Health and Human Services
  10. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy

    Amount: $133,835.00

    DESCRIPTION (provided by applicant): Interferon-alpha-2 (IFNa2) is indicated for the therapy of a variety of hematopoietic and solid tumors. However, its therapeutic potential has not been fully reali ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government